[1] G. Searles and R. J. McKendry, «Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature.,» J. Rheumatol., vol. 14, no. 6, pp. 1164–71, Dec. 1987.
[2] F. Schulze, M. Kasperkiewicz, D. Zillikens, and E. Schmidt, «Bullöses Pemphigoid,» Der Hautarzt, vol. 64, no. 12, pp. 931–945, Dec. 2013.
[3] N. Sathi, B. Chikura, V. V. Kaushik, R. Wiswell, and J. K. Dawson, «How common is methotrexate pneumonitis? A large prospective study investigates,» Clin. Rheumatol., vol. 31, no. 1, pp. 79–83, Jan. 2012.
[4] Y.-J. Kim, M. Song, and J.-C. Ryu, «Mechanisms underlying methotrexate-induced pulmonary toxicity,» Expert Opin. Drug Saf., vol. 8, no. 4, pp. 451–458, Jul. 2009.
[5] T. D’Elia, «Methotrexate-Induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis,» Inflamm. Allergy-Drug Targets, vol. 13, no. 1, pp. 25–33, Jan. 2014.
[6] S. Imokawa, T. Colby, K. Leslie, and R. Helmers, «Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients,» Eur. Respir. J., vol. 15, no. 2, 2000.
[7] B. Chikura, N. Sathi, S. Lane, and J. K. Dawson, «Variation of immunological response in methotrexate-induced pneumonitis,» Rheumatology, vol. 47, no. 11, pp. 1647–1650, 2008.
[8] C. Salliot and D. van der Heijde, «Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research,» Ann. Rheum. Dis., vol. 68, no. 7, pp. 1100–1104, Jul. 2009.
[9] «Schweizerische Gesellschaft für Rheumatologie Empfehlung Basistherapie Methotrexat,» pp. 3–5, 2010.
[10] V. Cottin, J. Tébib, B. Massonnet, P.-J. Souquet, and J.-P. Bernard, «Pulmonary Function in Patients Receiving Long-term Low-dose Methotrexate,» Chest, vol. 109, no. 4, pp. 933–938, 1996.
[11] L. G, «Acute Respiratory Distress Syndrome,» JAMA, vol. 307, no. 23, pp. 59–66, Jun. 2012.
[12] G. S. Alarcón, J. M. Kremer, M. Macaluso, M. E. Weinblatt, G. W. Cannon, W. R. Palmer, E. W. St Clair, J. S. Sundy, R. W. Alexander, G. J. Smith, and C. A. Axiotis, «Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.,» Ann. Intern. Med., vol. 127, no. 5, pp. 356–64, 1997.
1 Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987;14(6):1164–71.
2 Schulze F, Kasperkiewicz M, Zillikens D, Schmidt E. Bullöses Pemphigoid. Der Hautarzt. 2013;64(12):931–45.
3 Sathi N, Chikura B, Kaushik VV, Wiswell R, Dawson JK. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol. 2012;31(1):79–83.
4 Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf. 2009;8(4):451–8.
5 D’Elia T. Methotrexate-induced pneumonitis: heterogeneity of bronchoalveolar lavage and differences between cancer and rheumatoid arthritis. Inflamm Allergy-Drug Targets. 2014;13(1):25–33.
6 Imokawa S, Colby T, Leslie K, Helmers R. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2);373–81.
7 Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford). 2008;47(11):1647–50.
8 Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68(7):1100–4.
9 Schweizerische Gesellschaft für Rheumatologie. Empfehlung Basistherapie Methotrexat. 3/2017.
http://www.rheuma-net.ch/Richtlinien
10 Cottin V, Tébib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109(4):933–8.
11 The ARDS Definition Task Force. Acute respiratory distress syndrome.The Berlin definition. JAMA. 2012;307(23):2526–33. doi:10.1001/jama.2012.5669
12 Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.
Ann Intern Med. 1997;127(5):356–64.